Literature DB >> 8986589

Success rates following intracytoplasmic sperm injection are improved by using ZIFT vs IVF for embryo transfer.

J Boldt1, P Schnarr, A Ajamie, J Ketner, L Bonaventura, R Colver, L Reuter, J Jarrett.   

Abstract

PURPOSE: The purpose of this study was to analyze whether the mode of embryo transfer (ZIFT vs IVF) affected the outcome in intracytoplasmic sperm injection (ICSI) cycles. METHODS AND
RESULTS: Eighty-two ICSI cycles (42 ZIFT and 40 IVF) were analyzed. Several variables, including patient age and weight, numbers of mature eggs collected, injected, and fertilized, fertilization rate, number of fertilized eggs obtained per cycle, numbers of zygotes/embryos transferred, clinical pregnancy rate, and implantation rate, were compared. Mean patient age and weight were identical. The mean number of mature eggs collected and injected and fertilization rate were significantly higher in the ZIFT group, however, the mean numbers of zygotes/embryos transferred were identical. The clinical pregnancy and implantation rates in ZIFT cycles (52.3 and 23.2% respectively) were significantly higher than in IVF cycles (17.5 and 9.7%).
CONCLUSIONS: These data suggest that ZIFT is the more appropriate method for transfer of ICSI-derived embryos.

Entities:  

Mesh:

Year:  1996        PMID: 8986589     DOI: 10.1007/bf02066498

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  17 in total

1.  Female age is an important parameter to predict treatment outcome in intracytoplasmic sperm injection.

Authors:  R Abdelmassih; S Sollia; M Moretto; A A Acosta
Journal:  Fertil Steril       Date:  1996-03       Impact factor: 7.329

2.  Intracytoplasmic sperm injection: a novel treatment for all forms of male factor infertility.

Authors:  G D Palermo; J Cohen; M Alikani; A Adler; Z Rosenwaks
Journal:  Fertil Steril       Date:  1995-06       Impact factor: 7.329

3.  High fertilization and implantation rates after intracytoplasmic sperm injection.

Authors:  A C Van Steirteghem; Z Nagy; H Joris; J Liu; C Staessen; J Smitz; A Wisanto; P Devroey
Journal:  Hum Reprod       Date:  1993-07       Impact factor: 6.918

4.  A prospective randomized comparison of zygote intrafallopian transfer and in vitro fertilization-embryo transfer for nontubal factor infertility.

Authors:  M R Fluker; C G Zouves; M W Bebbington
Journal:  Fertil Steril       Date:  1993-09       Impact factor: 7.329

5.  Comparison of concurrent pregnancy rates for in-vitro fertilization--embryo transfer, pronuclear stage embryo transfer and gamete intra-fallopian transfer.

Authors:  D G Hammitt; C H Syrop; S J Hahn; D L Walker; C R Butkowski; J F Donovan
Journal:  Hum Reprod       Date:  1990-11       Impact factor: 6.918

6.  Factors of importance for the establishment of a successful program of intracytoplasmic sperm injection treatment for male infertility.

Authors:  P Svalander; A S Forsberg; A H Jakobsson; M Wikland
Journal:  Fertil Steril       Date:  1995-04       Impact factor: 7.329

7.  A simple approach to intracytoplasmic sperm injection.

Authors:  S H Atiee; T B Pool; J E Martin
Journal:  Fertil Steril       Date:  1995-03       Impact factor: 7.329

8.  Intracytoplasmic sperm injection facilitates fertilization even in the most severe forms of male infertility: pregnancy outcome correlates with maternal age and number of eggs available.

Authors:  R J Sherins; L P Thorsell; A Dorfmann; L Dennison-Lagos; L P Calvo; L Krysa; C B Coulam; J D Schulman
Journal:  Fertil Steril       Date:  1995-08       Impact factor: 7.329

9.  Intracytoplasmic sperm injection in dysmorphic human oocytes.

Authors:  M Alikani; G Palermo; A Adler; M Bertoli; M Blake; J Cohen
Journal:  Zygote       Date:  1995-11       Impact factor: 1.442

10.  Assisted reproductive technology in the United States and Canada: 1993 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry.

Authors: 
Journal:  Fertil Steril       Date:  1995-07       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.